Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4333058 | 0.83 | ALDH1A1 (0.31) | — | |
| SCHEMBL18113 | 0.79 | TSHR (0.31) | — | |
| SCHEMBL20303213 | 0.76 | — | — | |
| SCHEMBL1373738 | 0.76 | TSHR (0.33) | EPHX1 | |
| SCHEMBL537242 | 0.74 | ALDH1A1 (0.38) | EPHX1 | |
| SCHEMBL203812 | 0.74 | TSHR (0.33) | — | |
| SCHEMBL437089 | 0.74 | TSHR (0.33) | — | |
| SCHEMBL584323 | 0.73 | — | — | |
| SCHEMBL1899483 | 0.70 | ALDH1A1 (0.30) | — | |
| SCHEMBL1751456 | 0.70 | ALDH1A1 (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260138956-A1 | NOVEL COMPOUNDS AND USES THEREOF | RECURSION PHARMACEUTICALS INC (US) | 2026-05-21 | — | — | US | disclosed |
| EP-4743462-A1 | COMPOUNDS COMPRISING A NAPHTHYRIDINE OR PYRIDOPYRIMIDINE CORE AS PTC READ-THROUGH AGENTS | Tay Therapeutics Limited (GB) | 2026-05-20 | — | — | EP | disclosed |
| WO-2025061029-A1 | FGFR INHIBITORS AND METHODS OF USE THEREOF | 3H PHARMACEUTICALS CO., LTD. (CN) | 2025-03-27 | — | — | WO | disclosed |
| WO-2025012643-A1 | COMPOUNDS COMPRISING A NAPHTHYRIDINE OR PYRIDOPYRIMIDINE CORE AS PTC READ-THROUGH AGENTS | Tay Therapeutics Limited (GB) | 2025-01-16 | — | — | WO | disclosed |
| US-20230303498-A1 | HERBICIDAL CINNOLINE DERIVATIVES | SYNGENTA CROP PROTECTION AG (CH) | 2023-09-28 | — | — | US | disclosed |
| US-20230202989-A1 | COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2023-06-29 | — | — | US | disclosed |
| EP-4157823-A1 | COMPOUNDS | JANSSEN Pharmaceutica NV (BE) | 2023-04-05 | — | — | EP | disclosed |
| EP-4152932-A1 | HERBICIDAL CINNOLINE DERIVATIVES | Syngenta Crop Protection AG (CH) | 2023-03-29 | — | — | EP | disclosed |
| US-20230050653-A1 | ROCK INHIBITOR AND PREPARATION METHOD THEREFOR AND USE THEREOF | WUHAN LL SCIENCE AND TECHNOLOGY DEVELOPMENT CO., LTD. (CN) | 2023-02-16 | — | — | US | disclosed |
| EP-4059928-A1 | ROCK INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | Wuhan LL Science and Technology Development Co., Ltd. (CN) | 2022-09-21 | — | — | EP | disclosed |
| US-20050282805-A1 | thrombotic or an inflammatory disorders; improved factor XIa and/or plasma kallikrein inhibitory activity and selectivity, dosage requirment, costs or feasibility, side effect reduction; 4-(aminomethyl)-N-[2-phenyl-1-(4-pyridin-2-yl-1H-imidazol-2-yl)ethyl]-trans-cyclohexanecarboxamide | BRISTOL-MYERS SQUIBB COMPANY | 2005-12-22 | — | — | US | disclosed |
| EP-0592677-B1 | Beta-LACTAM COMPOUND AND CEPHEM COMPOUND, AND PRODUCTION THEREOF | OTSUKA KAGAKU KK (JP) | 2001-11-07 | — | — | EP | disclosed |
| EP-0623622-B1 | PROCESS FOR PRODUCING CEPHEM COMPOUND | OTSUKA KAGAKU KK (JP) | 1999-10-06 | — | — | EP | disclosed |
| US-5693792-A | INTERMEDIATES FOR CEPHALOSPORIN ANTIBIOTICS | OTSUGA KAGAKU KABUSHIKI KAISHA (JP) | 1997-12-02 | — | — | US | disclosed |
| US-5656754-A | REACTING AN ALLENYL-B-LACTAM COMPOUND WITH AN ORGANOTIN COMPOUND | OTSUKA KAGAKU KABUSHIKI KAISHA (JP) | 1997-08-12 | — | — | US | disclosed |
| US-5470972-A | Process for preparing examethylenecephem compounds | OTSUKA KAGAKU KABUSHIKI KAISHA (JP) | 1995-11-28 | — | — | US | disclosed |
| EP-0623622-A1 | PROCESS FOR PRODUCING CEPHEM COMPOUND | OTSUKA KAGAKU KABUSHIKI KAISHA (JP) | 1994-11-09 | — | — | EP | disclosed |
| EP-0592677-A1 | Beta-LACTAM COMPOUND AND CEPHEM COMPOUND, AND PRODUCTION THEREOF | OTSUKA KAGAKU KABUSHIKI KAISHA (JP) | 1994-04-20 | — | — | EP | disclosed |
| EP-0481604-A1 | Heterocyclic compounds | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1992-04-22 | — | — | EP | disclosed |
| US-4945160-A | Preparation of certain 7-substituted quinolones | WARNER-LAMBERT COMPANY (US) | 1990-07-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230202989-A1 | COMPOUNDS | NLRP3, NLRP1, IL1B | EPHX1 1537/4885 |
| US-20230303498-A1 | HERBICIDAL CINNOLINE DERIVATIVES | DDT, DERL1, MTX1 | EPHX1 122/4885 |
| US-20260138956-A1 | NOVEL COMPOUNDS AND USES THEREOF | SLC10A1, NR3C2, CYP2C8 | EPHX1 225/4885 |
| US-20230050653-A1 | ROCK INHIBITOR AND PREPARATION METHOD THEREFOR AND USE THEREOF | ROCK1, CYP11B1, CYP4A11 | EPHX1 1038/4885 |
| US-20050282805-A1 | thrombotic or an inflammatory disorders; improved factor XIa and/or plasma kallikrein inhibitory activity and selectivity, dosage requirment, costs or feasibility, side effect reduction; 4-(aminomethyl)-N-[2-phenyl-1-(4-pyridin-2-yl-1H-imidazol-2-yl)ethyl]-trans-cyclohexanecarboxamide | F11, TFPI, F12 | EPHX1 626/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.